2026– date –
-
Voyager Therapeutics Receives FDA IND Clearance for VY1706, First Tau-Targeted Gene Therapy, to Begin Alzheimer’s Disease Phase 1 Trial
Cell & Gene Therapy Review USA Overview Voyager Therapeutics announced that its Investigational New Drug (IND) application for VY1706, a tau-targeted gene therapy for Alzheimer's disease, has been cleared by the FDA. VY1706 is a potent a... -
BlueRock Therapeutics Initiates Patient Enrollment for Parkinson’s Disease iPSC-Derived Cell Therapy exPDite-2 Phase 3 Trial; Long-Term Follow-Up Data Imminent
Neurology Live USA Overview BlueRock Therapeutics has initiated patient enrollment for its Phase 3 exPDite-2 clinical trial, transplanting iPSC-derived dopaminergic neurons in Parkinson's disease patients. The trial will involve approxim... -
CRISPR Therapeutics Demonstrates Future Potential with Casgevy Approval, Leading Gene-Editing Market Through Pipeline Diversification
Intellectia.AI USA Overview CRISPR Therapeutics has established market leadership with the FDA approval of Casgevy, its gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia. In 2025, 64 patients receive... -
Fujifilm Reshuffles Life Sciences Leadership and Opens New Facility to Quadruple iPSC Manufacturing Capacity
FUJIFILM Holdings America Corporation Press Release USA Overview FUJIFILM Holdings America Corporation announced a reshuffle in the leadership of its life sciences group, with Delara Motlagh appointed as President and COO of FUJIFILM Cel... -
Avaí Bio Achieves GMP Milestone for Anti-Aging Cell Therapy; Beam Therapeutics Targets Accelerated Approval for BEAM-302; Sana Partners with Mayo Clinic for Type 1 Diabetes
Newswire.ca Canada Overview Multiple biotech companies reported significant advancements: Avaí Bio completed its GMP-grade Master Cell Bank (MCB) for the α-Klotho anti-aging program, paving the way for preclinical and clinical trials. Be... -
Sana Biotechnology to Initiate Hypoimmune Cell Therapy and In Vivo CAR T Trials This Year, with Data Expected Within 12 Months
TradingView USA Overview Sana Biotechnology is set to commence clinical trials for two key platforms this year: a hypoimmune cell therapy targeting Type 1 diabetes and an in vivo CAR T platform for oncology and autoimmune diseases. Initi... -
Made Scientific and Pluristyx Announce Integrated iPSC Development & Manufacturing Partnership to Accelerate Next-Generation iPSC-Derived Cell Therapies
PR Newswire USA Overview Made Scientific, a cell therapy CDMO, and Pluristyx, an iPSC platform technology provider, announced an integrated iPSC development and manufacturing partnership. This collaboration aims to accelerate the clinica... -
Fate Therapeutics Presents FT819/FT839 Data at EULAR 2026: Rapid, Sustained Improvement and Favorable Safety Profile in SLE Patients
GlobeNewswire (Fate Therapeutics Press Release) USA Overview Fate Therapeutics presented data from its off-the-shelf CAR T-cell programs, FT819 and FT839, at the 2026 European Congress of Rheumatology (EULAR) Annual Meeting. FT819 demons... -
Cynata Therapeutics to Announce Phase 3 iPSC-Derived MSC Results for Knee Osteoarthritis in June; Acute GVHD Phase 2 Nears Completion
Regen Report Australia Overview Cynata Therapeutics is set to release top-line results from its Phase 3 clinical trial, 'STOP-OA,' for knee osteoarthritis (KOA) using iPSC-derived mesenchymal stem cells (iPSC-MSC). The KOA trial database... -
Intellia Therapeutics Sees Steady Progress with HAE Therapy Lonvo-Z and ATTR Amyloidosis Therapy Nex-Z; FDA Lifts Clinical Hold on Nex-Z
Seeking Alpha USA Overview Intellia Therapeutics has demonstrated steady progress in the clinical development of Lonvo-Z for hereditary angioedema (HAE) and Nex-Z for ATTR amyloidosis. Positive data reported from the Phase 3 HAELO study ...
